SCHEMBL12876017

SCHEMBL12876017

COc1cc(C)cc(-c2csc(Cn3cc(C(=O)O)cn3)n2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.41
RAB9A P51151 3/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PTGS2 P35354 3/20 0.41
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
MAPT P10636 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CSNK2A1 P68400 2/20 0.38
ALKBH1 Q13686 2/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
KLKB1 P03952 1/20 0.37
KMT2A Q03164 3/20 0.37
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37
OPRK1 P41145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876016 0.89 MEN1 (0.39) MEN1RAB9AKDM4EALDH1A1NPC1
SCHEMBL1198836 0.87 RXRA (0.42) MEN1RAB9AKDM4EALDH1A1NPC1
SCHEMBL1198568 0.86 MEN1 (0.56) MEN1RAB9AKDM4EALDH1A1NPC1
SCHEMBL1197517 0.86 CSNK2A1 (0.53) MEN1RAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL12875895 0.86 L3MBTL1 (0.39) MEN1RAB9AKDM4EALDH1A1NPC1
SCHEMBL12875908 0.86 L3MBTL1 (0.39) MEN1RAB9AKDM4EALDH1A1NPC1
SCHEMBL12875802 0.86 L3MBTL1 (0.39) MEN1RAB9AKDM4EALDH1A1NPC1
SCHEMBL12875968 0.85 L3MBTL1 (0.41) RAB9AKDM4EALDH1A1NPC1SMN1; SMN2
SCHEMBL12875728 0.83 ALDH1A1 (0.41) MEN1RAB9AKDM4EALDH1A1PPARD
SCHEMBL12875918 0.83 SIRT5 (0.40) MEN1RAB9AKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MEN1 2661/4885RAB9A 2507/4885KDM4E 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.